

Amendments to the Claims:

The listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claim 1. (currently amended) A therapeutic composition for treating glaucoma comprising a combination of pharmaceutically effective amounts of drugs ~~consisting essentially of comprising~~ (i) a Rho kinase inhibitor selected from the group consisting of (R)-trans-N-(pyridin-4-yl)-4-(1-aminoethyl)cyclohexane carboxamide, (R)-(+)-N-(1H-pyrrolo[2,3-b]pyridin-4-yl)-4-(1-aminoethyl)benzamide, 1-(5-isoquinolinesulfonyl)-homopiperazine and 1-(5-isoquinolinesulfonyl)-2-methylpiperazine, or a salt or an ester thereof and (ii) a prostaglandin selected from the group consisting of isopropyl unoprostone, latanoprost, travoprost and bimatoprost, or a salt or ester thereof, and optionally a pharmaceutically acceptable carrier.

**Claim 2. (currently amended)** A therapeutic composition for treating glaucoma which comprises a combination of pharmaceutically effective amounts of drugs ~~consisting essentially of~~ comprising (i) a Rho kinase inhibitor selected from the group consisting of (R)-trans-N-(pyridin-4-yl)-4-(1-aminoethyl)cyclohexane carboxamide, (R)-(+)-N-(1H-pyrrolo[2,3-b]pyridin-4-yl)-4-(1-aminoethyl)benzamide, 1-(5-isoquinolinesulfonyl)-homopiperazine and 1-(5-isoquinolinesulfonyl)-2-methylpiperazine, or a salt or an ester thereof and a (ii) prostaglandin selected from the group consisting of isopropyl unoprostone, latanoprost, travoprost and bimatoprost, or a salt or an ester thereof, wherein the actions of the Rho kinase inhibitor and the prostaglandin are complemented and/or enhanced by each other, and optionally a ~~pharmacuetically~~ pharmaceutically acceptable carrier.

**Claims 3 to 20. (canceled)**

**Claim 21. (previously presented)** The therapeutic composition for treating glaucoma as claimed in claim 1, wherein the combination of drugs is selected from the group consisting of (i) (R)-(+) -N-(1H-pyrrolo[2,3-b]pyridin-4-yl)-4-(1-aminoethyl)benzamide dihydrochloride and isopropyl unoprostone;

(ii) (R)-(+) -N-(1H-pyrrolo[2,3-b]pyridin-4-yl)-4-(1-aminoethyl)benzamide dihydrochloride and latanoprost;

(iii) 1-(5-isoquinolinesulfonyl)-homopiperazine dihydrochloride and isopropyl unoprostone; and

(iv) 1-(5-isoquinolinesulfonyl)-homopiperazine dihydrochloride and latanoprost.

**Claim 22. (canceled)**